Brought to you by 
IPO nets $295mm for Gossamer Bio
Feb 2019
Executive Summary
Gossamer Bio Inc. (developing therapies for immune diseases, inflammation, and cancer) netted $295mm through its initial public offering of 19.8mm common shares (including the overallotment) at $16. The company had originally intended to sell 14mm shares.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
IPO nets $295mm for Gossamer Bio
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice